The cost of drug discovery continues to rise while the output of new NDAs continues to fall. Consequently it has never been more important to address attrition rates in drug discovery and development. Early indication of toxicity in a molecule or lead family means that discovery resources can be directed either at other chemical series if these are available or towards ‘breeding’ out undesirable properties. Gentronix and Apredica have come together, building on the strengths of each to provide a cost effective package of in vitro toxicology services that meet the needs of Pharmaceutical and Biotechnology companies alike. Whether you are looking to ease internal bottlenecks in your own toxicology and ADME functions or have compounds to progress but no internal resource in expert areas: we ...Read more
Receive your quote directly from Gentronix Ltd..